Targeted nanotechnology for cancer imaging

Abstract

Targeted nanoparticle imaging agents provide many benefits and new opportunities to facilitate accurate diagnosis of cancer and significantly impact patient outcome. Due to the highly engineerable nature of nanotechnology, targeted nanoparticles exhibit significant advantages including increased contrast sensitivity, binding avidity and targeting specificity. Considering the various nanoparticle designs and their adjustable ability to target a specific site and generate detectable signals, nanoparticles can be optimally designed in terms of biophysical interactions (i.e., intravascular and interstitial transport) and biochemical interactions (i.e., targeting avidity towards cancer-related biomarkers) for site-specific detection of very distinct microenvironments. This review seeks to illustrate that the design of a nanoparticle dictates its in vivo journey and targeting of hard-to-reach cancer sites, facilitating early and accurate diagnosis and interrogation of the most aggressive forms of cancer. We will report various targeted nanoparticles for cancer imaging using X-ray computed tomography, ultrasound, magnetic resonance imaging, nuclear imaging and optical imaging. Finally, to realize the full potential of targeted nanotechnology for cancer imaging, we will describe the challenges and opportunities for the clinical translation and widespread adaptation of targeted nanoparticles imaging agents.

PEG-coated gold nanoparticles attenuate β-adrenergic receptor-mediated cardiac hypertrophy

“…1,2 In particular, gold nanoparticles (AuNPs) are a potential candidate for the development of diagnostic and therapeutic methods, due to their unique physical, chemical, optical, and pharmacological properties. For example, gold cores are inert, stable, biocompatible, and have low toxicity.…”

Nanoformulations for Therapy of Pancreatic and Liver Cancers

“…Thus, strategies that stimulate enhanced distribution of a therapeutic are an unmet need. Other noteworthy reviews on nanotechnological advancements for cancer imaging and therapy include Toy et al [89], Kaittanis et al [90], Barar and Omidi [91] and Muthu et al [92].…”

Integration of imaging into clinical practice to assess the delivery and performance of macromolecular and nanotechnology-based oncology therapies

“…Furthermore, liposome formulations of iodinated contrast agents have been evaluated in patients [103] and have been used to examine response to radiation treatment in a murine sarcoma model [104]. Additionally, gold nanoparticles targeting HER2, endothelial growth factor receptor (EGFR), folate receptor (FR), and prostate specific membrane antigen (PSMA) have been used in preclinical studies as CT contrast agents for targeted imaging of tumors (reviewed in [105]). For example, HER2 targeted gold nanoparticles coated with PEG were used for CT imaging of murine breast cancer xenografts, showing significantly enhanced detection and visualization of millimeter-sized tumors [106].…”